Recently under the new leadership of veteran Sedor, the company has restructured its operations and staffing, added new product in pediatric pain medicine, added new patent in Japan and has a number of drugs in the pipeline, this stock is set for a genuine turn around.
Sedor stepped in to other failing companies in the past and re structured them for buyouts - expect this stock to make higher lows/highs over the coming months.
Consensus buyout figure is $3, the stock previously traded comfortably in $8 range. Its 52 week range is 0.39 - 4.24. Has bounced off its lows to consolidating in the high 0.50's and now in mid 0.60s. Its seems as though the dust has settled and investors are seeing genuine opportunity here once again.